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Objectives: The first objective was to investigate the in vitro activity of telithromycin against respiratory tract
pathogens in comparison with other antimicrobial agents. The second objective was to identify the influence
of the erm(B) and mef(A) genes on the susceptibility of Streptococcus pneumoniae to telithromycin.
Methods: The in vitro activity of telithromycin against S. pneumoniae, Moraxella catarrhalis and Haemo-
philus influenzae, isolated from the UK and 40 macrolide-resistant S. pneumoniae from four different
countries was compared with a variety of antimicrobial agents. The 140 isolates were examined for the pres-
ence of the erm(B) and mef(A) genes. The impact of 5% CO2 on susceptibility testing was also investigated.
Results: Telithromycin showed greatest activity against S. pneumoniae, but also had good activity against
M. catarrhalis and H. influenzae, which was independent of their resistance profiles to other antibiotics. The
MIC90 of telithromycin for S. pneumoniae was 0.12 mg/L, which was 64-fold lower than the lowest macrolide
MIC; 21% of the S. pneumoniae were macrolide resistant. Thirty-eight per cent of the macrolide-resistant
strains were erm(B)-positive and 62% were mef(A)-positive, but no strain contained both genes. The activity
of telithromycin was similar to that of azithromycin against both M. catarrhalis and H. influenzae, Erythro-
mycin was slightly less active: 1% and 8% of M. catarrhalis and H. influenzae, respectively, were resistant to
erythromycin, but none were resistant to telithromycin. Five per cent of the S. pneumoniae strains and 4% of
the H. influenzae strains changed from telithromycin susceptible to non-susceptible entirely because of the
incubation conditions. The MIC50s and MIC90s of S. pneumoniae, M. catarrhalis and H. influenzae increased
by one dilution when incubated in CO2.
Conclusions: Telithromycin has shown high in vitro activity against S. pneumoniae, including those strains
that are macrolide susceptible and resistant as well as M. catarrhalis and H. influenzae. This study has
also demonstrated that there is no cross-resistance between erythromycin and telithromycin. The impact of
5% CO2 on susceptibility testing should be investigated further before providing definite guidelines on
telithromycin susceptibility testing.
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Introduction
Resistance to antimicrobial agents is a particular problem in community-
acquired respiratory tract infections (CARTIs). In some countries
macrolide resistance now exceeds penicillin resistance in Strepto-
coccus pneumoniae.1 Between 10% and 30% of Haemophilus
influenzae and 85–100% of Moraxella catarrhalis worldwide are
β-lactamase producers. In the UK, erythromycin A resistance in
S. pneumoniae was higher than penicillin resistance by 7.7%.1
Telithromycin is a ketolide, which represents a new generation of
antimicrobial agents capable of overcoming these resistance prob-
lems. Telithromycin has activity against all three respiratory tract
pathogens regardless of their resistance profiles.2,3
The purpose of this study was to evaluate the in vitro activity
of telithromycin in comparison with a variety of antimicrobial
agents against macrolide-susceptible and -resistant S. pneumoniae,
M. catarrhalis and H. influenzae isolated over the same time period
as the PROTEKT study, 1999–2001, from the UK. As the number of
macrolide-resistant S. pneumoniae identified from the Edinburgh
and Leeds collections was low, a cohort of macrolide-resistant iso-
lates from Europe and America were also tested against telithro-
mycin to investigate the activity of telithromycin against resistant
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
*Corresponding author. Tel: +44-131-650-8270; Fax: +44-131-651-1385; E-mail: fwalsh@staffmail.ed.ac.uk
 at M
aynooth U
niversity on Septem
ber 23, 2016
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
F. Walsh et al.
794
isolates. This ensured that a diverse group of macrolide-resistant
S. pneumoniae isolates were included in the study.
Materials and methods
Bacterial strains
One hundred strains each of S. pneumoniae, M. catarrhalis and H. influ-
enzae from the UK were investigated. The S. pneumoniae were isolated
from Leeds and Edinburgh, the M. catarrhalis from Edinburgh, Leeds
and Wales and the H. influenzae from Edinburgh and Glasgow between
1999 and 2001. Forty macrolide-resistant S. pneumoniae isolates were
donated from the USA, Canada, Belgium and Italy. These isolates were
donated by Dr Zhong (Abbott Laboratories, USA), Dr de Azavedo
(University of Toronto, Canada), Dr Lagrou (Rega Institute for Medical
Research, Belgium) and Dr Marchese (University of Genova, Italy),
respectively. The control strains consisted of S. pneumoniae NCTC
13593, Staphylococcus aureus NCTC 6571, H. influenzae NCTC 11931
and a laboratory reference strain of M. catarrhalis.
Antimicrobial agents
The antimicrobial agents were stored and prepared according to the
manufacturers’ guidelines. Telithromycin (Aventis Pharma Ltd), erythro-
mycin (David Bull Laboratories, Warwick, UK), azithromycin (Pfizer
Ltd), clindamycin (Sigma), moxifloxacin (Bayer), gemifloxacin (Smith-
Kline Beecham Pharmaceuticals) and linezolid (Pharmacia and Upjohn)
were tested in vitro.
Minimum inhibitory concentrations
The MICs were determined on Columbia agar base supplemented with
5% defibrinated horse blood for S. pneumoniae and M. catarrhalis and on
chocolate Columbia agar plates for H. influenzae according to the BSAC
guidelines for susceptibility testing.4 The MICs were determined by the
standard agar doubling dilution method. The MIC plates containing
telithromycin were incubated in both air and 5% CO2, at 37°C. All other
plates were incubated in air at 37°C. The MIC tests were repeated at least
once for each strain.
The antimicrobial breakpoints used were those from the BSAC guide-
lines except for telithromycin for which the NCCLS tentative break-
points were used.5,6 Resistance to the antimicrobial agents was assigned
at the following MIC values: telithromycin ≥4 mg/L for S. pneumoniae
and ≥16 mg/L for H. influenzae, erythromycin ≥1 mg/L, azithromycin
≥2 mg/L and clindamycin ≥1 mg/L.
Characterization of macrolide resistance mechanism
S. pneumoniae strains with an erythromycin MIC ≥ 1 mg/L or an azithro-
mycin MIC ≥ 2 mg/L isolated from the UK and the 40 donated isolates
were screened for the presence of the erm(B) and mef(A) genes. S. pneu-
moniae strains were emulsified in 200 µL of MilliQ water and boiled for
10 min in order to extract the total DNA. The supernatant was used as the
DNA template in PCR experiments. The PCR conditions and primers for
the detection of erm(B) and mef(A) genes are those described previously
by Sutcliffe et al.7 and Tait-Kamradt et al.8 The strains were tested for
both genes at the same time. The erm(B) and mef(A) primers were added
to the same reaction mixture with a MgCl2 concentration of 4 mM.
Results
Susceptibility profiles
Telithromycin had the second lowest MIC90 of all the antimicrobial
agents tested against S. pneumoniae as shown in Table 1. The
telithromycin MIC90 was 64-fold lower than the lowest macrolide
MIC90. While the MIC90 of clindamycin was the same as that of
telithromycin, the upper limit of the range was substantially higher.
Telithromycin activity against the 40 macrolide-resistant S. pneu-
moniae was the same as that against the 100 UK isolates with varying
macrolide susceptibilities. The range endpoint (1 mg/L) was lower
than that for the UK isolates (2 mg/L) and the MIC90s (0.25 mg/L)
were identical. Thus telithromycin activity was not affected by the
macrolide resistance mechanisms of these strains. Gemifloxacin and
moxifloxacin both had high activity against S. pneumoniae with their
highest MICs at 0.12 and 0.5 mg/L, respectively. Linezolid did not
perform as well as the other antimicrobial agents. The fluoroquino-
lones had the greatest activity of the antimicrobial agents tested
against M. catarrhalis. Their MIC90s ranged from 0.016 to 0.06 mg/L.
The MIC90s of the macrolides were 0.12 and 0.25 mg/L. There was
little difference between the performance of telithromycin and the
macrolides. Clindamycin and linezolid both had low activity against
M. catarrhalis in vitro with MIC90s of 4 mg/L. Telithromycin had
relatively good activity against H. influenzae with an MIC90 of 2 mg/L.
It had lower MIC50 and MIC90 values than erythromycin by two
dilutions. For H. influenzae, clindamycin and linezolid had the same
MIC90s of 16 mg/L. Once again the fluoroquinolones performed with
the highest activity and low MIC90s of 0.004–0.016 mg/L.
Table 1. Antimicrobial activities against S. pneumoniae, M. catarrhalis and H. influenzae
MIC range [MIC50/MIC90] (mg/L)
Antimicrobial 
agent
Macrolide-resistant 
S. pneumoniae (40)
Streptococcus 
pneumoniae (100)
Moraxella 
catarrhalis (100)
Haemophilus  
influenzae (100)
Telithromycin CO2 0.016–1 [0.06/0.25] 0.016–2 [0.12/0.25] 0.032–1 [0.12/0.25] 0.008–8 [2/4]
Telithromycin air 0.008–1 [0.032/0.12] 0.032–0.5 [0.06/0.12] 0.032–4 [1/2]
Erythromycin 0.008–128 [0.06/8] 0.06–1 [0.25/0.25] 0.12–16 [4/8]
Azithromycin 0.008–16 [0.12/16] 0.032–0.25 [0.06/0.12] 0.06–8 [1/2]
Clindamycin 0.008–32 [0.06/0.12] 1–8 [2/4] 0.032–32 [4/16]
Moxifloxacin 0.032–0.5 [0.12/0.25] 0.016–0.12 [0.06/0.06] 0.004–0.12 [0.016/0.016]
Gemifloxacin 0.008–0.12 [0.032/0.06] 0.002–0.016 [0.008/0.016] 0.002–0.12 [0.002/0.004]
Linezolid 0.12–4 [1/2] 2–8 [4/4] 0.5–64 [8/16]
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Correlation between telithromycin and erythromycin
The correlation between telithromycin MIC and that of erythromycin
and clindamycin for S. pneumoniae are detailed in Table 2. These
results indicated that the five isolates with the highest telithromycin
MICs were erythromycin resistant but clindamycin susceptible.
Eight of the 12 isolates with a telithromycin MIC of 0.12 mg/L were
erythromycin resistant, and three of these were also clindamycin
resistant. The S. pneumoniae isolates resistant to clindamycin had
telithromycin MICs of 0.032–0.12 mg/L and were also erythromycin
resistant.
Effect of CO2 incubation
When the MIC plates containing telithromycin were incubated in 5%
CO2 (Table 1) the range and MIC90 for S. pneumoniae increased by
one dilution and the MIC50 increased by two dilutions. The S. pneu-
moniae range endpoint increased from 1 to 2 mg/L when incubated in
CO2. With a telithromycin MIC of 2 mg/L a S. pneumoniae strain is
categorized as intermediate using the BSAC guidelines and resistant
using the French guidelines. Five per cent of S. pneumoniae were
telithromycin resistant and 2% or 5% had intermediate resistance
using the French guidelines and BSAC guidelines, respectively,
when measured in CO2. With regard to M. catarrhalis and H. influ-
enzae the MIC50 and MIC90 both increased by one dilution when
incubated in CO2. The approved telithromycin breakpoint for
H. influenzae is 4 mg/L for susceptible, 8 mg/L for intermediate and
≥16 mg/L for resistant. Strains with an MIC of 4 mg/L in air were
categorized as susceptible but with CO2 incubation showed an MIC
of 8 mg/L and were categorized as intermediate.
Resistance levels
Telithromycin had the lowest resistance levels, considerably lower
than either the macrolides or the lincosamide. There was no resist-
ance to telithromycin in either S. pneumoniae, M. catarrhalis or
H. influenzae using the NCCLS breakpoints (Table 3). Using the
guidelines suggested by Soussy et al.,9 i.e. telithromycin suscep-
tibility <0.5 mg/L and resistance ≥2 mg/L, telithromycin inter-
mediate resistance of 1 mg/L for Gram-positive bacteria, the resistance
levels for S. pneumoniae increased slightly. One per cent of S. pneu-
moniae isolates had telithromycin intermediate resistance. In com-
parison, 21% of the S. pneumoniae population was erythromycin
resistant and 6% were resistant to clindamycin. In M. catarrhalis the
entire population were found to be clindamycin resistant while one
strain was also erythromycin resistant. No resistance to telithromycin
or azithromycin was observed. Erythromycin resistance was at 8%
for H. influenzae, whereas azithromycin resistance was at 1%.
Mechanisms of macrolide resistance
The 21 macrolide-resistant S. pneumoniae strains consisted of eight
erm(B)-positive and 13 mef(A)-positive strains. There were no
strains containing both genes. All the strains except two Edinburgh
isolates had matching phenotype and genotype, i.e. erm(B)-positive
strains were macrolide and clindamycin resistant and mef(A)-
positive strains were resistant only to the macrolides. The Edinburgh
erm(B)-positive strains had clindamycin MICs of 0.12 and 0.25 mg/L.
The 40 donated strains comprised 29 erm(B)-positive and 11 mef(A)-
positive strains. No strains contained both genes. Within this group
four strains were also erm(B)-positive but clindamycin susceptible
with MICs of 0.12 or 0.25 mg/L.
Discussion
Susceptibility testing of respiratory tract pathogens is often per-
formed in a CO2 environment to ensure that the bacteria grow to the
required concentration. In a CO2 environment the pH of the test
medium decreases. Macrolide activity is adversely affected by this
pH decrease. In order to investigate whether this was also true for the
ketolide telithromycin, susceptibility testing was also carried out in
5% CO2. This study has shown that the MIC of telithromycin
increased when incubated in 5% CO2 in comparison with air incu-
bation. Five per cent of the S. pneumoniae strains and 4% of the
H. influenzae strains changed from telithromycin susceptible to non-
susceptible entirely because of the incubation conditions. The
MIC50s and MIC90s of S. pneumoniae, M. catarrhalis and H. influen-
zae increased by one dilution when incubated in CO2. These results
indicated that the pH of the medium also caused an increase in
Table 2. Comparison of telithromycin susceptibility and erythromycin and clindamycin resistance profiles of S. pneumoniae
n, number of isolates.
Telithromycin MIC (n) 0.008 (10) 0.016 (16) 0.032 (35) 0.06 (22) 0.12 (12) 0.25 (3) 0.5 (1) 1 (1)
Erythromycin resistant % (n) 10 (1) 0 (0) 14 (5) 9 (2) 67 (8) 100 (3) 100 (1) 100 (1)
Clindamycin resistant % (n) 0 (0) 0 (0) 6 (2) 4.5 (1) 25 (3) 0 (0) 0 (0) 0 (0)
Erythromycin and clindamycin 
resistant % (n)
0 (0) 0 (0) 6 (2) 4.5 (1) 25 (3) 0 (0) 0 (0) 0 (0)
Erythromycin and clindamycin 
susceptible % (n)
90 (9) 100 (16) 86 (30) 91 (20) 33 (4) 0 (0) 0 (0) 0 (0)
Table 3. Resistance profiles of S. pneumoniae, M. catarrhalis and H. 
influenzae
Percentage resistance
S. pneumoniae M. catarrhalis H. influenzae
Telithromycin 0 0 0
Erythromycin 21 1 8
Azithromycin 14 0 1
Clindamycin 6 100 97
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telithromycin MIC. An increase in the telithromycin mode MIC and
MIC range was also detected by Bemer-Melchoir et al.10 when the
susceptibility of Streptococcus pyogenes was tested in 5–6% CO2.
However, unlike the results described by Bemer-Melchoir et al.,
which suggested that the MIC of telithromycin in CO2 increased only
for erythromycin-resistant isolates, no such correlation was identi-
fied with S. pneumoniae, M. catarrhalis or H. influenzae. In this and
previous studies macrolide resistance has been associated mainly
with S. pneumoniae rather than M. catarrhalis or H. influenzae.1
The French guidelines recommend testing telithromycin activity
against S. pneumoniae in air as well as CO2 in order to confirm resist-
ance for clinical characterization. However, no such recommenda-
tions were presented for H. influenzae. The results of this study
suggest that telithromycin susceptibility should be tested in air for all
three organisms. Therefore, the French committee need to investi-
gate the effect of incubation in CO2 for H. influenzae also. The latest
BSAC guidelines recommend that S. pneumoniae and H. influenzae
are incubated in CO2 and M. catarrhalis is incubated in air for suscep-
tibility testing. Under these conditions the tentative susceptibility to
telithromycin point for the three organisms is <0.5 mg/L. As incu-
bation in CO2 has affected each of the three organisms tested in this
study it would be appropriate for the BSAC to investigate this further
with these and other organisms and larger populations before provid-
ing definite guidelines on telithromycin susceptibility testing and
breakpoints.11
In the Alexander Project, erythromycin resistance in S. pneu-
moniae from the UK was at 13.6% in 1996 and 7.2% in 1997.12 How-
ever, this study has shown that the resistance level in Edinburgh and
Leeds for the same period was 21% in S. pneumoniae. The percentage
of H. influenzae resistant to erythromycin is 8%; however, none are
telithromycin resistant and almost all are azithromycin susceptible.
The results of the correlation between telithromycin, erythro-
mycin and clindamycin identified a pattern similar to that described
previously by Johnson et al.13 All the erythromycin- and clindamycin-
resistant isolates were susceptible to telithromycin. The telithro-
mycin MICs for the isolates that were erythromycin resistant alone or
in combination with clindamycin resistance were higher than those
for the susceptible isolates. The S. pneumoniae with an erythro-
mycin-resistant and clindamycin-susceptible phenotype were less
susceptible to telithromycin than those resistant to both. The isolates
with the highest telithromycin MICs were erythromycin resistant
and clindamycin susceptible. Therefore, in agreement with Johnson
et al.13 telithromycin was less affected by the erm(B)-positive than by
the mef(A)-positive isolates. Thus, while telithromycin can over-
come both resistance mechanisms as all isolates were telithromycin
susceptible, the macrolide efflux system and to a lesser extent the
target methylation do reduce telithromycin activity.
Telithromycin has previously been shown to have activity against
macrolide-resistant S. pneumoniae. This finding has been borne out
in these results as it was tested against 61 macrolide-resistant S. pneu-
moniae isolates. Telithromycin had consistently lower MICs than
erythromycin for all the bacteria tested. No resistance to telithro-
mycin was found in S. pneumoniae, M. catarrhalis or H. influenzae.
The 21 macrolide-resistant S. pneumoniae isolates from the UK com-
prised erm(B)- and mef(A)-positive isolates in a ratio of 1:2. Usually
in Europe the erm(B) gene predominates and the converse is found in
the USA. This study contradicts this finding in so far as there was a
greater number of mef(A)-positive UK isolates than erm(B)-positive
isolates. Isolates that were erythromycin and clindamycin resistant
have been attributed a constitutive macrolide resistance phenotype
and those that were erythromycin resistant and clindamycin suscep-
tible an inducible macrolide resistance phenotype.14 Therefore, the
results of this study indicate that the constitutive resistance pheno-
type predominates in the isolates investigated in this study. Thus
telithromycin has activity against inducible macrolide-resistant
S. pneumoniae and also against the inducible macrolide-resistant
S. pneumoniae investigated in this study. The high overall activity of
telithromycin against the three respiratory pathogens and almost no
resistance indicates that telithromycin has good potential for the
treatment of RTIs, including those caused by macrolide-resistant
strains.
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